Medication Overuse Headache Clinical Trial
Official title:
Orbitofrontal Cortex (OFC) Influence on Addictive Behaviour in Medication Overuse Headache (MOH) Deriving From Migraine
Medication Overuse Headache (MOH) is an illness affecting about 1,5 % of the general
population. It is characterized by chronic headache occurring for at least 15 days a month,
by a use of antimigraine drugs during at least 3 months for more than 10 days a month (for
ergots, triptans, opiate derivates and combined analgesics) or for more than 15 days a month
(for simple analgesics). The chronic headache must have occurred during the period of
antimigraine drug abuse and the headache must have returned to its episodical pattern after
withdrawal of antimigraine drugs. But, about 50% of the MOH patients will relapse during the
first year following the antimigraine drugs withdrawal.
The pathophysiology of MOH is still largely unknown, and the role of antimigraine drug abuse
in the transformation from migraine through MOH is not fully understood.
We recently explored cerebral metabolism in these MOH patients using (18F)FDG-PET (Fluoro
Dexoxy Glucose Positon Emission Tomography) comparing them with controls. Results showed a
hypometabolism in the OFC, which persist immediately after the antimigraine drugs
withdrawal. A similar pattern is observed in varied substance related disorders and should
be a marker of addictive behaviour. It can be linked with difficulties in the
decision-making process, which can be explored by the Iowa Gambling Task (IGT) test.
Several questions are still unanswered. What will this abnormality become in the long term ?
Is it predictive of susceptibility for relapse? Can it be linked to a specific psychological
profile (addictive behaviour)?
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05720819 -
Biofeedback-VR for Treatment of Chronic Migraine
|
N/A | |
Terminated |
NCT02583425 -
Pilot Study of DFN-11 Injection in Medication Overuse Headache
|
Phase 2 | |
Recruiting |
NCT03655184 -
An Observation Study on Neuropsychology and Serum Melatonin Level in Patients With Medication Overuse Headache
|
||
Active, not recruiting |
NCT02993289 -
Is Detoxification Needed in Medication-overuse Headache?
|
N/A | |
Active, not recruiting |
NCT05608642 -
Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment
|
N/A | |
Recruiting |
NCT03671681 -
Mindfulness Therapy for Chronic Migraine
|
N/A | |
Completed |
NCT01078012 -
Short Intervention for Medication Overuse Headache (MOH) - Pilot
|
N/A | |
Completed |
NCT03767062 -
Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches
|
N/A | |
Recruiting |
NCT01754571 -
CBT in Patients With Medication Overuse Headache
|
Phase 0 | |
Completed |
NCT02435056 -
Medication Overuse Headache (MOH) and an Innovative Approach
|
N/A | |
Recruiting |
NCT05452239 -
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
|
Phase 4 | |
Completed |
NCT01044251 -
Frovatriptan as a Transitional Therapy in Medication Overuse Headache
|
Phase 2 | |
Completed |
NCT00918671 -
Medication-overuse Headache: 4 Years Follow up
|
||
Completed |
NCT04336267 -
Anodal tDCS in Chronic Migraine With Medication Overuse
|
N/A | |
Enrolling by invitation |
NCT01752439 -
Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache
|
N/A | |
Completed |
NCT04772742 -
Eptinezumab in Adults With Migraine and Medication Overuse Headache
|
Phase 3 | |
Completed |
NCT04228809 -
tDCS in Chronic Migraine With Medication Overuse (Edisom)
|
N/A | |
Not yet recruiting |
NCT05334927 -
China HeadAche DIsorders RegiStry
|
||
Completed |
NCT04090333 -
Endocrinological Profile in Patients With Medication-overuse Headache Before and After Withdrawal Therapy
|
||
Recruiting |
NCT01317992 -
Ibudilast in the Treatment of Medication Overuse Headache
|
Phase 1/Phase 2 |